MONDAY INVESTOR DEADLINE: Robbins Geller Rudman & Dowd Announces that Rocket Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

Core Viewpoint - The Rocket Pharmaceuticals class action lawsuit alleges violations of the Securities Exchange Act of 1934, focusing on misleading statements regarding the safety and clinical trial protocol of its gene therapy product RP-A501 [1][4]. Group 1: Lawsuit Details - The lawsuit is titled Ho v. Rocket Pharmaceuticals, Inc. and seeks to represent purchasers of Rocket Pharmaceuticals securities [1]. - A subsequent case, Yankov v. Rocket Pharmaceuticals, Inc., has also been filed [1]. - The lawsuit claims that Rocket Pharmaceuticals failed to disclose serious adverse events, including patient deaths, related to its clinical trials [4][5]. Group 2: Clinical Trial Allegations - Rocket Pharmaceuticals is accused of providing misleading information about its Phase 2 pivotal trial for RP-A501, particularly regarding the safety of the treatment and the introduction of a new immunomodulatory agent without proper disclosure [4]. - On May 27, 2025, the U.S. FDA placed a clinical hold on the RP-A501 study after a patient suffered a serious adverse event leading to death, which was not disclosed to investors at the time of the protocol amendment [5]. Group 3: Legal Process - Investors who purchased Rocket Pharmaceuticals securities during the class period can seek to be appointed as lead plaintiff in the lawsuit [6]. - The lead plaintiff will represent the interests of all class members and can choose a law firm to litigate the case [6]. Group 4: About Robbins Geller - Robbins Geller Rudman & Dowd LLP is a leading law firm specializing in securities fraud and shareholder litigation, having recovered over $2.5 billion for investors in 2024 alone [7]. - The firm has been ranked 1 in securing monetary relief for investors in securities class action cases for four out of the last five years [7].